Introduction The risk for brain injury manifested as cerebral palsy is higher in very preterm
born children than in term. Prenatal administration of magnesium sulfate (MgSO4) has been …

Background Administration of magnesium sulphate (MgSO 4) to women with imminent
preterm birth at< 34 weeks is an evidence-based antenatal neuroprotective strategy to …

Background Ordinary meta‐analyses indicate that magnesium sulphate (MgSO4) treatment
in women at imminent risk for preterm delivery decreases the offspring's risk of cerebral …

Objective To evaluate a slower (compared with a standard) infusion rate of the loading dose
of magnesium sulphate for preterm fetal neuroprotection as a strategy to reduce maternal …

Key content: The prevalence of preterm birth is increasing and owing to advances in
neonatal care, more infants are surviving. However, in parallel with this, the incidence of …

Magnesium sulfate in some dosage given before very preterm pregnancy delivery is
beneficial for fetal neuroprotection. The exact dose, duration, and timing of administration to …

Abstract Background: Preterm delivery< 32-week gestation is associated with significant
neurodevelopmental morbidity ranging from mild delay to profound disability. Several …

Abstract Background: Magnesium sulphate (MgSO 4) has been recommended for fetal
neuroprotection to prevent cerebral palsy, with national societies adopting new guidelines …

Background: Cerebral palsy (CP) is a motor and/or cognitive dysfunction affecting the low
birth weight (LBW) infants, and infants delivered preterm before 34 gestational weeks …

Introduction Magnesium sulfate is used world‐wide to treat pregnant women at imminent risk
of preterm delivery in order to protect the brain of the premature infant. Previous research …